Aroma therapy for dementia.

No. 2 Cottage, Cotbank of Barras, Stonehaven, UK, AB39 2UH.
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 02/2003; DOI: 10.1002/14651858.CD003150
Source: PubMed

ABSTRACT Complementary therapies have become more commonly used over the last decade and have been applied to a range of health problems, including dementia. Of these, aroma therapy is reported to be the most widely used in the British National Health Service (Lundie 1994) and might be of use for people with dementia for whom verbal interaction may be difficult and conventional medicine of only marginal benefit. Aroma therapy has been used for people with dementia to reduce disturbed behaviour (e.g. Brooker 1997), promote sleep (e.g. Wolfe 1996), and stimulate motivational behaviour (e.g. MacMahon 1998).
To assess the efficacy of aroma therapy as an intervention for people with dementia.
The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched on 29 October 2002 to find all relevant trials using the terms: aroma therap*, "aroma therap*", "complementary therap*", "alternative therap*" and "essential oil". The CDCIG Register contains records from all major health care databases and is updated regularly. Additionally, relevant journals were hand searched, and 'experts' in the field of complementary therapies and dementia contacted.
All relevant randomized controlled trials (RCTs) were considered. A minimum length of trial and requirements for a follow-up were not included, and participants in included studies had a diagnosis of dementia of any type and severity. The review considered all trials using fragrance from plants defined as aroma therapy as an intervention with people with dementia. Several outcomes were considered in this review, including cognitive function, quality of life, and relaxation.
The titles and abstracts extracted by the searches were screened for their eligibility for potential inclusion in the review, which revealed 2 RCTs of aroma therapy for dementia. Neither of these had published results in a form that we could use. However, individual patient data from one trial were obtained (Ballard 2002) and additional analyses performed. Analysis of co-variance was used for all outcomes, using a random effects model.
The additional analyses conducted revealed a statistically significant treatment effect in favour of the aroma therapy intervention on measures of agitation and neuropsychiatric symptoms.
Aroma therapy showed benefit for people with dementia in the only trial that contributed data to this review, but there were several methodological difficulties with this study. More well designed large-scale RCTs are needed before conclusions can be drawn on the effectiveness of aroma therapy. Additionally, several issues need to be addressed, such as whether different aroma therapy interventions are comparable and the possibility that outcomes may vary for different types of dementia.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Partant d’observations empiriques issues d’un atelier d’écriture mis en œuvre au sein d’une unité de soins de longue durée, ce travail montre que l’écriture, dans le cadre d’un atelier, est en mesure de diminuer l’intensité des troubles du comportement des patients atteints de maladie d’Alzheimer et apparentées (MAA) aux stades modérés à sévères. En se décalant d’une perspective déficitaire des manifestations des MAA, la recherche intègre les points de vue psychanalytique et phénoménologique pour définir les fondements conceptuels de l’atelier d’écriture. Les résultats fournissent des données supplémentaires en faveur des indications de l’approche non médicamenteuse dans la prise en soin des troubles comportementaux.
    NPG Neurologie - Psychiatrie - Gériatrie 10/2014; DOI:10.1016/j.npg.2014.08.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive complaints are common in the geriatric population. Older adults should routinely be asked about any concerns about their memory or thinking, and any cognitive complaint from the patient or an informant should be evaluated rather than be attributed to aging. Several screening instruments are available to document objective impairments and guide further evaluation. Management goals for patients with cognitive impairment are focused on maintaining function and independence, providing caregiver support, and advance care planning. There are currently no treatments to effectively prevent or treat dementia. Increasing appreciation of the heterogeneity of Alzheimer disease may lead to novel treatment approaches. Copyright © 2015 Elsevier Inc. All rights reserved.
    Medical Clinics of North America 03/2015; 99(2):311-335. DOI:10.1016/j.mcna.2014.11.006 · 2.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bien que leur efficacité n’ait pas souvent été étudiée et de surcroît démontrée, les traitements non médicamenteux font partie intégrante de la prise en charge des personnes atteintes de démence neurodégénérative, en particulier de maladie d’Alzheimer. Une évaluation correcte et rigoureuse est pourtant essentielle pour: connaître avec fiabilité les traitements non médicamenteux qui sont réellement efficaces, savoir comment les mettre en place, définir quels patients pourront en bénéficier réellement et déterminer, le cas échéant, quels effets indésirables ou inconvénients y sont associés. Si le schéma d’étude classique de l’essai comparatif randomisé reste la référence pour évaluer un traitement non médicamenteux, d’autres types d’études (avant- après, ici-ailleurs, études d’observation) peuvent être employés même si leurs biais potentiels doivent être scrupuleusement évalués. Les essais évaluant des traitements non médicamenteux ont des aspects méthodologiques spécifiques, comme la difficulté à respecter l’insu, ou encore la complexité dans le choix du comparateur et dans la standardisation de l’intervention. Il existe néanmoins des solutions pour faire face à ces difficultés et pour contribuer à améliorer la qualité des essais. Enfin, un traitement non médicamenteux ne devrait pas être mis en oeuvre sans disposer d’informations préalables sur son efficacité potentielle et ses éventuels effets indésirables. Abstract Although their efficacy has not been frequently studied or demonstrated, non-pharmacologic treatments are an integral part of caring for those suffering from neurodegenerative dementia, particularly Alzheimer’s disease. However, proper and rigorous evaluation is essential in order to reliably understand which non-pharmacologic treatments are actually effective, how to implement them, how to define which patients may actually benefit from them and to determine, where necessary, which adverse effects or disadvantages are associated with them. Although the classic randomised controlled trial remains the reference to evaluate a nonpharmacologic treatment, other types of study (before-after, here-elsewhere, observational studies) may also be used even if their potential bias must be scrupulously assessed. Trials evaluating non-pharmacologic treatments have specific methodological aspects, such as the difficulty in respecting blinding, as well as the complexity in selecting the comparator and in the standardisation of intervention. Nevertheless, solutions exist to overcome these difficulties and to contribute to improving the quality of these trials. Finally, a non-pharmacologic treatment should not be implemented without having prior information regarding efficacy and adverse effects.
    Les cahiers de l année gérontologique 09/2013; 5(1-2):3-12. DOI:10.1007/s12612-013-0354-6


Available from